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In conservation physiology, a common difficulty in assessing the effects of the stress
response in animals is maintaining consistent elevation of stress hormones. It has be-
come a goal of researchers to experimentally elevate the stress hormone corticosterone
(CORT) via a system that can be implanted into an animal and release CORT at a con-
trolled rate. Using rattlesnakes as a model animal, this project investigated the prepara-
tion and characterization of CORT-loaded ethylene vinyl acetate (EVA) microparticles to
experimentally elevate CORT levels. The EVA/CORT microparticles were prepared by
an emulsification-solvent evaporation technique and characterized via FTIR, SEM, and
TGA. The release of CORT from the microparticles was investigated in vitro at 25 ◦C in
a reptile Ringer’s solution over a period of five days at one day intervals. The CORT
released was evaluated using a TGA analysis approach by analyzing the percent weight
loss of CORT after each day. The prepared microparticles were found to have a wide
range of morphologies and exhibited irregular shapes. Rather than displaying a distinct
weight loss corresponding to CORT, the TGA data showed delayed degradation tem-
peratures of the EVA/CORT microparticles as well as larger weight loss percents that
corresponded to the acetic acid content of the EVA. These findings do not support the
mechanism of CORT release from the microparticles. Therefore it can not be concluded
that an EVA/CORT microparticle system was successfully prepared.
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Introduction
1.1 Background
For the past few decades, a popular trend in ecology and evolution has been the emer-
gence of conservation physiology into its own discipline. Conservation science has con-
tinually been a vital force for ensuring biodiversity and sustainability, however it has
not been until recently that researchers began to use physiological methods to gather
data on pressing conservation problems. An important example is the discovery of
the effects of dichloro-diphenyl-trichloroethane (DDT) on the reproductive behavior of
predators as outlined by Wikelski and Cooke. When the connection was made between
DDT and the failure of reproduction in many exposed predators, the use of DDT in
substances was banned in major parts of the world. This DDT tragedy supports the
potential insights that physiological studies of animals can reveal. They can determine
cause and effect relationships that are important for conservation and even monitor the
effectiveness of current conservation management methods (Wikelski and Cooke, 2006).
In this spirit, conservation physiology can assess the increasing influence humans
have on natural systems. To supply for our own needs and expansion, humans have
been known to induce habitat destruction, overexploitation of resources, and biological
exploitation. In turn, these human activities decrease the number of suitable habitats
for wildlife (Dickens and Romero, 2013). These events pose serious threats to disrupt-
ing the life-history stage of animals by inducing a stress response that animals have
not adapted to handle. The key component to study these threats is the physiologi-
cal response of stress in animals, i.e. the fluctuation of hormones in animals resulting
from such events. By studying these responses in great deal, conservation biologists
can provide an assessment of the consequences that human influence has on species
reproduction rates and population numbers, two key metrics of biodiversity.
1.2 Review of Literature
1.2.1 Stress in Organisms
The definition for the state of stress that animals experience due to external factors is
typically debated due to the wide variability in historical experimental methodologies.
Nonetheless, it has been generally accepted that, broadly, stress is a state an organism
experiences when they are faced to cope with unpredictable and adverse conditions
(Claunch et al., 2017). Coping with such capricious conditions is not typically part of
the life history cycle of animals and thus are not adapted to handle such conditions.
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These conditions are therefore a source of perturbation for animals. Factors that can
induce such perturbation can include those from physical environments (e.g. storms,
climate change, etc.), changes in the number of major predators, and changes that alter
social status which consequently reduces the access to resources (Wingfield, 2005).
Augmented with stressors that result from human influence, these perturbation fac-
tors likely become intensified when inflicted on the animal. Even more so, if perturba-
tion is prolonged or frequent, then there is a higher potential for severe stress. However,
all organisms must be able to cope with any unpredictable event at some stage in their
life history cycle (Wingfield, 2005). Although, it has been theorized that conditions that
induce chronic stress in many wild organisms are expected to increase over the next
coming decades (Wingfield, 2005). This is the result of many factors such as climate
change and the increasing influence of humans on natural habitats. Depending on the
event, the stress response experienced can be divided into two categories: acute, short-
term and chronic, long-term.
Acute, short-term responses are typically referred to as a collection of physiological
and behavioral changes that are thought to help an animal survive in the wild (Sapolsky,
Romero, and Munck, 2000). The role of such changes is similar to the process of allosta-
sis. The purpose is to temporarily stop normal life-history functions in order to quickly
counteract the impact the stressor had on the animal and allow the animal to return back
to its normal activities (i.e. homeostasis) (Dickens and Romero, 2013). Chronic, long-
term responses occur when the stress response system of an animal has been pushed far
beyond its normal capacity. This can be the result from either fluctuating intensity of a
stressor and/or persistence of the stressor. Typically, chronic, long-term responses have
a major impact on the health of the animal, however it is worth noting that there is vari-
ation in the effects of both responses based on the magnitude of the response (Dickens
and Romero, 2013).
1.2.2 Role of Corticosterone
Paramount to understanding the stress response of animals is the physiological reac-
tion once a stressor is encountered. To cope with the capricious conditions, organisms
typically respond by elevating levels of circulating glucocorticoids (GCs), such as corit-
sol and/or corticosterone (CORT) (Claunch et al., 2017). It is believed that these hor-
mones typically help mediate any ongoing or pending stress response via elevation
permitting other features of the stress response to emerge, and/or the levels actively
inducing the stress response (Sapolsky, Romero, and Munck, 2000). Although, severe
elevation of these hormones can have negative effects on animals. Studies has shown
that the severe, chronic stress response can influence the expression of a suite of traits in
many taxa, including reproduction, immune system function, behavior, thermoregula-
tion, and protein metabolism (Claunch et al., 2017; Wingfield et al., 1998; Martin, 2009;
Landys, Ramenofsky, and Wingfield, 2006; Wingfield and Sapolsky, 2003).
As a result of studies on such chronic stress responses, physiological stress responses
and baseline CORT levels are often used to assess the health of many populations of an-
imals in the wild. This is so because CORT and other glucocorticoids can be correlated
with both environmental chance and fitness parameters (Busch and Hayward, 2009).
Additionally, such research can be used to predict future growth and reproduction, in-
sights that are continually valuable for conversation science. It has become apparent in
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recent literature that such physiological studies in ectotherms (such as rattlesnakes) can
yield interesting insights into the effects of elevated CORT levels since because of their
slow metabolism, they can endure chronic CORT elevation for longer periods of time
(Landys, Ramenofsky, and Wingfield, 2006; Claunch et al., 2017).
1.2.3 Challenges with Corticosterone
The key to test hypotheses about effects of chronic stress responses is the ability to exper-
imentally manipulate CORT levels. Rather than exposing organisms to acute stressors
to stimulate a chronic stress response, sustained CORT levels via direct experimental
manipulation has been theorized to better mimic CORT levels during chronic stress
(Claunch et al., 2017). Experimental studies of this sort are rare partially due to difficul-
ties in experimentally manipulating elevated CORT levels, such as repeated application
of a stimulus to attain CORT concentration (Sopinka et al., 2015).
There have recently been several studies that attempted to evaluate the effects of
elevated CORT levels in wild populations. French et al. reported manipulated CORT
concentrations in female tree lizards to test the role CORT plays in the regulation of
limiting resources between reproductive and immune systems (French et al., 2007).
To experimentally manipulate CORT levels, an implantable gelling material was used
that allowed slow release of the hormone. The implant contained poly(ethylene gyl-
col)diacrylate mixed with CORT in liquid form which after injection experiences a gelling
reaction that releases the CORT (French et al., 2007). Though effective at elevating CORT
concentrations, the gelling material provided the elevation due to an initial pulsatile re-
lease of CORT soon after injection. In contrast, to evaluate the effects of elevated CORT
levels, it is important to provide a means of controlled release of CORT for a prolonged
period of time that allows the researcher to aptly measure changes in behavioral and/or
reproduction traits.
A study by Claunch et al. reported the use of an implant as well to experimen-
tally manipulate CORT levels in a wild population of snakes. The implant consisted of
silastic tubing infused with crystalline CORT which would allow for controlled release
of CORT throughout the ends of the cylindrical implant. Moderate sustained release
of CORT provided a basis for the determination of behavioral changes in rattlesnakes
due to chronic CORT elevation. However, the results suggest that rattlesnakes do not
respond to chronic CORT elevation the same way as other organisms (Claunch et al.,
2017). The intentions of this study are to similarly experimentally elevate CORT lev-
els in rattlesnakes via a controlled release system that maintains CORT levels at longer
periods of time.
1.2.4 Polymers for Drug Delivery
To study the effects of elevated hormone levels in animals, attention has been brought
to mechanisms in which hormone levels can be altered in humans. This functional-
ity is often regarded in science and engineering as drug delivery, where devices and
systems are designed to control the release of a drug. In this context, "drug release"
refers to the process in which drug solutes migrate from initial positions in the system
to the outer surface and then to the release medium (Langer, 1990). Though seemingly
straightforward, this process is affected by multiple variables such as the physiochem-
ical properties of the drug, the structural characteristics of the material system, and
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FIGURE 1.1: Hypothetical plasma drug concentration profiles of multiple
doses of conventional drug forms and single doses of sustained release
and controlled release formulations. Adapted from Misal et al.
possible interactions between these factors (Fu and Kao, 2010). It is of continual inter-
est to researchers to select materials considering these driving factors and the specific
purpose of the system.
Typically, drugs follow a peak and valley release profile as depicted in Figure 1.1. Af-
ter administration, the drug level increases to a desired therapeutic level slowly. Then
due to variable conditions inside the body, the concentration of the drug continues to
increase past this desired level and then decreases slowly after a critical point.This there-
fore results in fluctuations of the plasma drug level between when it is ineffective or pos-
sibly toxic (Misal et al., 2013). Similarly, many tablet formulations have been designed
to produced a "sustained" release of the drug where the plasma drug concentration re-
mains in the therapeutic level longer before coming back down (Figure 1.1). To solve
this problem, mechanisms have been designed to produce drug release profiles where
the drug concentration reaches the desired therapeutic level inside the body and stays
there for a desired period of time. This zero-order release kinetics behavior is commonly
referred to by researchers as controlled release. Depending on the polymer and drug,
such systems can be designed to maintain consistent drug levels from hours to years
(Langer, 1990).
Both non-degradable and degradable polymers have dominated as the primary ma-
terials of interest for controlled drug delivery in literature. Generally, the mechanisms of
release from these polymers can be classified as diffusion driven, chemically-controlled,
or solvent-controlled. In the case of diffusion driven systems, Fick’s law of diffusion
provides a mathematical model for the transport of drugs through polymeric matrices.
It is described by Grassi and Grassi that the model of Fick’s law refers to the transport
of the drugs when the polymer relaxation time is much greater than the solvent dif-
fusion time (Grassi and Grassi, 2005). Non-degradable polymers are typically used in
such diffusion-controlled systems in the form of a matrix or membrane reservoir sys-
tem (Fu and Kao, 2010). In chemically-controlled systems, drugs can be attached to
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FIGURE 1.2: Diagram of the Progestasert system. Adapted from Salem &
Baskin.
the polymer via pendant chain chemistry where the drugs are cleaved by water which
initiates release of the drug (Langer, 1990). Because of the required influx of water,
degradable polymers comprise the majority of these systems. Solvent controlled sys-
tems are based on the influx of a solvent (i.e. water) that causes the polymer to swell
which creates a medium for the drug to be released into the surrounding environment
(Langer, 1980). Like chemical-controlled systems, solvent-controlled systems also typi-
cally use degradable polymers activate the swelling mechanism of release. A majority
of the aforementioned systems typically control the release of drugs on the order of a
few days. To study behavioral traits of ectotherms, drug delivery systems would have
to be modeled to release hormones on the order of thirty days or longer. Perhaps the
most popular use of controlled release systems that sustain drug levels this long (years)
are contraceptive implants. The Progestasert system shown in Figure 1.2, for example,
controls the delivery of the hormone progesterone for one year from an intrauterine im-
plant (Salem and Baskin, 1992). Using implants of this sort, the level of the hormone is
kept at a constant level where treatment becomes effective without inducing any side
effects for the patient. Even more so, because of the long life of the implant, patient com-
pliance is less of a concern since there is no requirement of consistent administration of
the hormone. Since the development of the Progestasert system, many other contracep-
tive implants have been developed that have the same functionality, such as Implanon
and Nexaplanon (Schneider et al., 2017).
Contraceptive implants of this sort are based on a membrane reservoir system using
a non-biodegradable polymer. Reservoir-type devices refer to those that have an inert
coating material around a matrix of the the same coating material and the drug ((Fung
and Saltzman, 1997), Figure 1.3). The coating material functions as a rate-controlling
membrane that allows for zero-order release of the drug over time. This release rate
remains relatively constant and is not affected by concentration, but is more related to
physical parameters, such as the membrane thickness and surface area of the device,
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FIGURE 1.3: Schematic representation of membrane-reservoir controlled
release systems and matrix controlled release systems, respectively.
Adapted from Fung & Saltzman.
and permeability of the membrane (Langer, 1980). In contrast, matrix-only type devices
tend to be Fickian diffusion driven, which is affected by the concentration gradient,
diffusion distance, and degree of swelling which all can impact the final drug release
profile of the system (Figure 1.3) (Fu and Kao, 2010).
1.2.5 Ethylene Vinyl Acetate for Controlled Release Systems
A majority of membrane reservoir delivery systems have been fabricated using ethylene
vinyl acetate (EVA) copolymer as the material for the matrix as well as the inert mem-
brane. EVA is a transparent thermoplastic copolymer of ethylene and vinyl acetate (VA)
monomers in which the VA segments are randomly distributed throughout the ethylene
polymer backbone. The VA content in commonly available EVA ranges between 1 and
40 wt.%. Typically, many chemical and mechanical properties arise from the VA content
such as crystallinity, melting point, stiffness, and even polarity (Schneider et al., 2017).
An important property relevant to membrane systems that arises from VA content is
the permeability of the copolymer. As the VA content increases, the overall rigidity of
the copolymer chain decreases and consequently the polymer becomes more rubbery
and permeable therefore allowing a greater drug release rate to be observed (Tallury,
Alimohammadi, and Kalachandra, 2007).
In the pharmaceutical industry, EVA is most commonly processed by extrusion (Schnei-
der et al., 2017). The extrusion process, usually involving a hot melt, is advantageous
for producing systems that depend on large surface area to volume ratios. Though,
other techniques have been reported to process EVA for applications including but not
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limited to controlled-release systems. A report by Kalachandra, Dongming, and Offen-
bacher reported a solvent casting technique for the production of EVA thin film drug
delivery devices. The methodology uses dichloromethane and 40 wt% VA content EVA
to prepare the polymer thin films that encased tetracycline, minocycline, or nystatin
(Kalachandra, Dongming, and Offenbacher, 2002). Other processing techniques include
injection moulding, dip coating, spray coating, sintering, and coacervation (Schneider
et al., 2017). One of the oldest and perhaps most industrially feasbile techniques of coac-
ervation has been microencapsulation by emulsification solvent evaporation, which is
the methodology of interest in this study.
1.2.6 Microencapsulation By Emulsification Solvent Evaporation
The procedure of microencapsulation by emulsification solvent evaporation is concep-
tually straightforward. First, it involves the emulsification of a polymer solution-containing
drug into a second, liquid phase containing an emulsifier to form a dispersion of drug-
polymer solvent droplets (Watts, Davies, and Melia, 1990). Second, the solvent is re-
moved from the droplets by evaporation leaving a suspension of drug-containing poly-
mer microspheres. The microspheres can then be separated, washed, and dried. This
technique can be tailored to produce microspheres of a wide size range, from 200 nm
to several hundred microns where the structure of the microspheres is continually the
drug dispersed through a matrix as a solid or a molecular dispersion (Watts, Davies,
and Melia, 1990).
The role of the emulsifier in the microencapsulation is the short-term stabilization of
suspended polymer droplets. This stabilization process prevent concomitantly prevents
aggregation and coalesence of the polymer (Watts, Davies, and Melia, 1990). According
to Watts, Davies, & Melia, this sequence of events is potentially short since after evapo-
ration occurs and the polymer droplets begin to harden, aggregation and coalesence is
not expected to occur. Most commonly used emulsifiers include polymeric stabilizers
such as gelatin, PVA, and sodium methylcellulose. These stabilizers are popular due to
the potential increase in solution viscosity these can produce (Watts, Davies, and Melia,
1990). Higher solutions viscosities have been reported in literature to produce distorted
microspheres of varying shapes (Cavalier, Benoit, and Thies, 1986).
A critical aspect to the microencapsulation procedure is the selection of a solvent for
the emulsification. Important criteria for selecting a solvent are the ability to dissolve the
EVA polymer and the drug, immiscibility with the emulsifier, lower boiling point, and
low reported toxicity (Watts, Davies, and Melia, 1990). An interesting study reported
by Chowdary & Babu investigated the surface effects and permeability of the resulting
microspheres by using different solvents. The various solvents tested were cyclohex-
ane, dichloromethane, 1,2-dichloroethane, and chloroform using a similar technique to
that explained above. High permeability and drug release was observed in the case of
microspheres prepared using as the solvent for the polymer EVA (Chowdary and Babu,
2003). The order of increasing permeability of the microspheres employing the various
solvents was cyclohexane, dichloromethane, 1,2-dichloroethane, and chloroform. It is
believed that the solvent used induces nano-sized surface effects on the microspheres
which thus increase or decrease the permeability of the EVA depending on the solvent.
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The efficacy of microspheres produced by the emulsification solvent evaporation
method has been well studied using a variety of different solvents and drugs in liter-
ature. For example, Chowdary, Enturi & Jagadish reported the use of EVA microcap-
sules to control the release of pioglitazone, an anti-diabetic medication. The emulsifi-
cation technique utilized sodium carboxy methyl cellulose as the emulsifier and EVA
dissolved in chloroform to form the homogenous polymer solution (Chowdary, Enturi,
and Jagadish, 2011). It is interesting to note that the authors reported that both zero-
order and first-order kinetic models are equally appliable to describe the release data.
This was largely determined by an analysis of correlation coefficients and analyzing the
data to an equation that yield different modes of transport. This equation is known as
the Ritger-Peppas equation and is described as
Mt
M∞
= k1tn (1.1)
where Mt is the amount of solute transported at time t, k is a constant incorpo-
rating characteristics of the particle system that makes up the formulation, and n is a
determined exponent where n=1 corresponds to zero-order release, n=0.5 corresponds
to Fickian diffusion, and where 0.5 < n < 1corresponds to non-Fickian diffusion (Ritger
and Peppas, 1987).
1.3 Proposed Research
The research being proposed in this study combines both conservation physiology and
materials engineering. It is our goal to create an implant similar to past studies (Claunch
et al., 2017; French et al., 2007) that can elevate CORT levels in rattlesnakes for a pro-
longed period of time. It is critical to maintain consistent CORT levels over the course of
the thirty day period to allow accurate determination of effected behavioral traits as well
as biological traits. We plan to achieve this using an EVA polymer device that encacp-
sulates the CORT within its core, which would allow controlled released via diffusion
out of the EVA, thus yielding a zero-order release profile.
We anticipate using an emulsification-solvent evaporation technique to produce the
EVA/CORT system. The result will be microparticles that encapsulate the CORT within
the particle core at potentially different concentrations. Here, we describe the system as
’microparticles’ because different analytical chemistry techniques would be required to
determine the exact formulation of the microparticle (i.e. if it is a microsphere, a mono-
lithic system of EVA and CORT, or if it is a microcapsule). Figure 1.4 shows schematically
the difference between these formulations. In the absence of determining which exact
formulation is produced, the system will be referred to as microparticles.
Electron microscopy will be utilized to investigate the morphology of the resultant
microparticles. Infrared spectroscopy will be used to examine details of the chemical
structure of the microparticles after processing to determine any effects of processing on
the chemistry of the materials. Testing of the viability of the microparticles to control the
release of CORT will be done in vitro in a reptile Ringer’s solution using thermogravi-
metric analysis (TGA) as an indirect measure of CORT release. Once the release profile
has been determined, the system can be evaluated on its efficacy of releasing CORT at a
controlled rate in order to maintain CORT elevation. Data from this study can help yield
valuable insights into how human interactions continually affect the stress response in
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FIGURE 1.4: Schematic comparison of the two different formulations
of microparticles that can be produced from the emulsification-solvent
evaporation technique.
organisms and even more so how detrimental that response can be to a snakes’, and
reptiles’ in general, life history cycle.
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Materials and Methods
2.1 Materials
The materials used in this study include ethylene-co-vinyl acetate (EVA), 12% VA con-
tent, crystalline corticosterone (CORT), cyclohexane (anhydrous) as the organic solvent
to dissolve the EVA, 0.5 wt% sodium carboxymethyl cellulose (Na-CMC) as the emulsi-
fier of the microparticles, and a reptile Ringer’s solution composed of various propor-
tions of salts listed below in Table 2.1. All chemicals were used as-received.
TABLE 2.1: Components of the Reptile Ringer’s Solution
Component Amount
KCl 0.35 g
KH2PO4 0.1625 g
MgSO4 0.29375 g
NaHCO3 1.68 g
NaCl 8 g
CaCl2 0.2775 g
DI Water 1 L
2.2 Preparation of EVA/CORT Microparticles
2.2.1 Initial Process
The method used in this study to prepare the EVA/CORT microparticles was a tech-
nique called emulsification-solvent evaporation. In this process, an emulsifier is used
to precipitate a solution of the copolymer and drug as a fine dispersion of droplets,
where following this step, the solvent used to dissolve the polymer is evaporated leav-
ing behind only the polymer and drug encapsulated in microparticles. The exact proce-
dure is adapted from previous studies producing EVA microspheres and microcapsules
(Chowdary and Babu, 2001; Chowdary, Enturi, and Jagadish, 2011; Tallury, Alimoham-
madi, and Kalachandra, 2007; Chowdary and Babu, 2003; Watts, Davies, and Melia,
1990).
The effectiveness of the emulsification-solvent evaporation technique for producing
microparticles was first tested by using EVA alone. First, a 1 wt% solution of Na-CMC
was created by dissolving 2 g of Na-CMC powder in 200 mL DI water using a Premier
Mill Corp. Series 2000 Laboratory Dispersator overhead mixer at approximately 1000
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RPM. 500 mg of EVA copolymer was then dissolved in 25 mL of cyclohexane at 30
◦C while magnetic stirring in order to form a homogenous polymer solution. Once a
homogenous polymer solution was obtained, 10 mL of the polymer solution was added
in a thin stream to the Na-CMC solution while continually stirring at approximately
1000 RPM to emulsify the added solution as fine droplets. The solvent, cyclohexane,
was then removed by continuous stirring at room temperature for 3 h.
After the solvent was allowed to evaporate for 3 h, the microparticles were collected
by gravimetric filtration. Using a ceramic funnel and filter paper with a pore size of
20-25 microns the Na-CMC solution and microparticle precipitates were separated by
filtering the Na-CMC solution overnight. After the microparticle precipitates were en-
tirely collected, they were washed repeatedly with DI water.
2.2.2 Process Optimization
To optimize the emulsification process and produce more discrete microparticles, the
conditions for creating the Na-CMC solution were altered, A 0.5 wt% solution of Na-
CMC was used by dissolving 1 g of Na-CMC powder in 200 mL DI water using the
overhead mixer at approximately 1000 RPM, similar conditions to that reported in lit-
erature (Chowdary and Babu, 2001; Chowdary and Babu, 2003; Chowdary, Enturi, and
Jagadish, 2011). Because the Na-CMC absorbs water rapidly, the Na-CMC was added
slowly in small amounts to the DI water in the mixer to prevent clumping of the Na-
CMC powder. Furthermore, to facilitate the ease of collecting the microparticles, vac-
uum filtration was used in place of gravimetric filtration using a Pro-Set 1 stage vacuum
pump.
2.2.3 Final Process
The final process included loading the microparticles with CORT. This was done simi-
larly as already discussed by dissolving 500 mg of crystalline CORT in the polymer solu-
tion (500 mg of EVA dissolved in 25 mL cyclohexane). Then, 10 mL of the CORT+polymer
solution was added in a thin stream to the Na-CMC solution under mixing conditions at
approximately 1000 RPM. This step included different conditions regarding the location
of where the thin stream was added in respect to the mixing paddle and the vortex. The
solvent, cyclohexane, was then removed via evaporation by continuous stirring at room
temperature for 3 h. After the solvent was allowed to evaporate for 3 h, the micropar-
ticles were collected by vacuum filtration and washed repeatedly with DI water. Once
washed, the microparticles were allowed to dry overnight, where afterwards they were
collected and stored at room temperature. The final emulsification-solvent evaporation
technique is shown schematically below in Figure 2.1.
2.3 Characterization of EVA/CORT Microparticles
2.3.1 Determination of Functional Groups
To determine the functional groups, and in extension, to validate the chemical composi-
tion of the resultant microparticles, fourier transform infrared spectroscopy (FTIR) was
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FIGURE 2.1: Final emulsification-solvent evaporation technique used in
this study.
utilized. Using a Jasco FTIR 4600, spectra were taken from 4000 to 400 cm−1 at 2.0 cm−1
resolution of single EVA and EVA/CORT microparticles.
2.3.2 Morphology of EVA/CORT Microparticles
To characterize the morphology of the resultant microparticles, sample sizes represen-
tative of each batch were observed under a scanning electron microscope (SEM - FEI
Quanta 200). The microparticles were mounted directly on to the SEM sample stub, us-
ing double sided sticking tape, and sputter coated with gold film under reduced pres-
sure. Particle sizes were determined by using an estimation by scale bar pixel method
of the obtained SEM images. This method consisted of determining the amount of pix-
els equivalent to the scale bar of the SEM image. Using that relationship, the diameter
of the particles were determined by measuring the amount of pixels that made up the
diameter of individual discrete particles.
2.4 In vitro Testing to Evaluate CORT Release
2.4.1 In vitro Method
To evaluate the release of CORT, the prepared EVA/CORT microparticles were tested in
vitro. The following process is shown schematically in Figure 2.2. 13 mg of EVA/CORT
microparticles from all batches were tested in 15 mL of reptile Ringer’s solution for each
day of study. The microparticles+Ringer’s solution were placed in a 25◦C water bath
and shaker table for five days, with samples taken at one day intervals. The microparti-
cles were recovered by the sample and separate method using filter paper, washed with
DI water, and later stored at room temperature. The in vitro drug release experiments
were run in duplicate for all batches.
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FIGURE 2.2: In vitro method used for testing CORT release.
2.4.2 Determination of CORT Release
To determine the action and amount of CORT release from the microparticles during in
vitro testing, thermogravimetric analysis (TGA) was used as an indirect measure. After
each day interval microparticles’ were sampled and separated, the microparticles were
run in a Mettler Toledo TGA/SDTA851 TGA at 10◦C/min from 23◦C to 500◦C. All TGA
data were converted to weight loss percent (wt%) in order to determine the weight loss
of each component of the microparticles during in vitro testing. Consequently, this data
would allow for an indirect method to construct a CORT release profile curve.
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Results and Discussion
3.1 FTIR Spectra
3.1.1 EVA Microparticles
The collected FTIR spectrum for the EVA microparticles alone is shown below in Figure
3.1. The spectrum appears to be representative of EVA due to the characteristic peaks for
both PE and VA. The spectrum contains broad peaks at around 2900 cm−1, 1420 cm−1,
and 720 cm−1, all corresponding to different vibrational modes (stretch, bend, and rock,
respectively) of the functional group methylene as reported in literature (D’Amelia et
al., 2016). The spectrum also appears to have significant peaks at 1740 cm−1, 1234 cm−1,
and 1015 cm−1. These peaks are attributed to the bonding modes present in the VA,
where 1740 cm−1 corresponds to C=O and 1234 cm−1 and 1015 cm−1 correspond to the
C-O bonds branching off from the polyethylene backbone (Figure 3.2) (Wang, Liu, and
Xiong, 2007; Meszlényi and Körtvélyessy, 1999).
The presence of these characteristic peaks in the EVA microparticles spectrum is
evidence that there is EVA in the resultant microparticles. However, it is interesting
to note the peak at around 2350 cm−1 that is typically not present in PE or VA spectra
reported in literature. These two conditions leads to the speculation that there were
possible effects of processing the as-received EVA into microparticle form.
FIGURE 3.1: FTIR spectrum of EVA microparticles.
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FIGURE 3.2: Chemical structure of EVA.
FIGURE 3.3: FTIR spectrum of EVA/CORT microparticles.
3.1.2 EVA/CORT Microparticles
The collected FTIR spectrum for the prepared EVA/CORT microparticles is shown in
Figure 3.3. Like the spectrum from the EVA microparticles in Figure 3.1, the spectrum
contains significant peaks at 2900 cm−1, 1740 cm−1,1420 cm−1, 1234 cm−1, 1020 cm−1,
and 720 cm−1. Using these observations in the data, it can be pointed out that these sig-
nificant peaks are characteristic of the EVA in the prepared EVA/CORT microparticles.
The difference between the spectrum collected from the EVA microparticles and
EVA/CORT microparticles is the presence of two moderate peaks at around 1650 and
1690 cm−1 in the EVA/CORT microparticles’ spectrum.The potential of these peaks rep-
resenting CORT in the prepared microparticles is a bit speculative due to the lack of
infrared spectroscopy studies on CORT. However, there is one study by Shah, Ashraf-
Khorassani & Taylor that reported the spectra of different steroids (including CORT) us-
ing supercritical-fluid chromatography (SFC)-FTIR (Shah, Ashraf-Khorassani, and Tay-
lor, 1988). In the study, the authors reported the spectrum of CORT to have one large,
broad peak at around 1700 cm−1 (Figure 3.4). The similarity in position of this reported
peak and the two preaks found in the EVA/CORT microparticles spectrum gives in-
sight to the potential presence of CORT in the microparticle system. However, without
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FIGURE 3.4: Published SFC-FTIR spectrum of CORT. Adapted from Shah,
Ashraf-Khorassani & Taylor.
further infrared spectroscopic analysis into the origin of the peak (that reported in liter-
ature and those found in the EVA/CORT microparticles), the true presence of CORT can
not be definitively determined. The presence of the peaks could be additive (where the
EVA/CORT spectrum is simply an addition of the EVA spectrum and CORT spectrum)
or it could be interactive, which would signify interaction between the EVA and CORT
during processing.
Furthermore, it is interesting to note also the presence of the double peak at around
2340 cm−1 in Figure 3.3. The presence of this peak in the spectrum for the EVA/CORT
microparticles as well points towards potential processing effects on the microparti-
cles. There is a possibility that this peak corresponds to remaining traces of the sol-
vent, cyclohexane, in the microparticle system. Such a finding is often the case with
emulsification-solvent evaportation processes that utilize toxic solvents such as cyclo-
hexane and dichloromethane (Watts, Davies, and Melia, 1990; O’Donnell and McGinity,
1997).
3.2 Location Results and Microparticle Yield
As discussed in Section 2.2.3, the final process for preparing the EVA/CORT micropar-
ticles utilized different conditions of where the stream of EVA+CORT was added to
the emulsification. The different locations included directly above the mixer paddle,
slightly further away from the mixer paddle, inside the vortex, and at the center of the
vortex. Despite the success of the technique in producing EVA microparticles as just
discussed, it was found that 50% (2 of the 4) of these conditions were unsuccessful in
producing discrete microparticles. Instead, the EVA+CORT mixture appeared to clump
up and agglomerate, thereby creating one large microparticle on the order of centime-
ters. A summary of these mixing conditions is displayed in Table 3.1. Because the the-
ory for this system requires discrete microparticles, those batches that produced single,
large microparticles (inside the vortex, and at the center of the vortex) were not used
in the subsequent methods of this study. The batches that produced discrete micropar-
ticles (above the mixer paddle and slightly further away from the mixer paddle) were
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used for the subsequent methods of this study and from on will be known as batch 1 (or
EVA/CORT-1) and batch 2 (or EVA/CORT-2), respectively.
TABLE 3.1: Different mixing locations used and result in producing dis-
crete microparticles.
Location Microparticles?
Directly above mixer paddle Yes
Inside the vortex No
Center of the vortex No
Further away from mixer paddle Yes
It is believed that for the locations that caused the EVA+CORT to clump up, the
shear force from the mixer paddle in the Na-CMC was not high enough in order to
precipitate the solution as droplets. Conversely, for the locations that did produce dis-
crete microparticles, the shear force was high enough, thus causing the stream to be
sheared and precipitate droplets of the EVA+CORT solution. The total yield, by mass,
of EVA/CORT-1 microparticles was 203 mg where the total yield of EVA/CORT-2 mi-
croparticles was 239 mg.
3.3 Morphology
3.3.1 EVA Microparticles
The morphology of all the microparticles produced in this study was analyzed using
SEM. Figure 3.5 below displays an SEM image of a sample of EVA microparticles with-
out CORT. Initially, it can be observed that a portion of the microparticles are not dis-
crete. Some of the microparticles are not necessarily particles of EVA, but moreover,
they are clusters of EVA. These few clusters of EVA are left out of the morphological
analysis, due to the difficulty in using a standard method (by pixels of the SEM image)
to evaluate their size.
Using the scale bar pixel method as described in Section 2.3.2, a summary of the mor-
phology of the EVA microparticles is displayed graphically by a histogram in Figure 3.5.
The size distribution was found to be relatively normal, with slightly more particles be-
ing on the larger end of the size distribution. The average diameter was found to be 831
microns. This particle size is similar to that reported in literature Chowdary and Babu,
2001; Chowdary and Babu, 2003; Chowdary, Enturi, and Jagadish, 2011, which thereby
points to the success of the technique used in this study for producing microparticles.
3.3.2 EVA/CORT Microparticles
Figure 3.6 below shows an SEM image of a representative sample of the entire EVA/CORT-
1 batch. Compared to EVA miroparticles, it can be initially pointed out that the EVA/CORT-
1 microparticles have a more irregular shape, and yet still consist of various ’clusters’ of
material. Figure 3.6 also displays the size distribution histogram of this overall sample
of EVA/CORT-1 microparticles. Unlike the EVA microparticles, these tend to be skewed
towards smaller particles, with a majority of the particles having a diameter in the range
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FIGURE 3.5: Left: SEM image of prepared EVA microparticles without
CORT. Right: Size distribution histogram of EVA microparticles without
CORT.
of 300-600 microns. The average diameter was found to be 734 microns, smaller than
the EVA microparticles without CORT.
FIGURE 3.6: Left: SEM image of prepared EVA/CORT-1 microparticles.
Right: Size distribution histogram of EVA/CORT-1 microparticles.
Comparatively, Figure 3.7 displays the SEM image and size distribution histogram
of a representative sample of the entire EVA/CORT-2 batch. Like EVA/CORT-1 mi-
croparticles, the second batch contained microparticles that are irregular in shape, with
various clusters dispersed throughout the sample. However, upon visual inspection, it
appears that the EVA/CORT-2 microparticles are larger. The size distribution histogram
shows that in this case, the EVA/CORT-2 microparticles have a more uniform size dis-
tribution, but with a majority of the particles having a diameter in a larger size range,
600-900 microns. Even more so, the average diameter was measured to be 886 microns,
larger than the average diameter for the EVA/CORT-1 microparticles.
These morphological results point towards an interesting correlation between the
location at which the EVA+CORT solution stream was added and the resultant size of
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the microparticles. For the case of EVA/CORT-1, the EVA+CORT stream was added
directly above the mixer paddle, where it is believed that the shear force is the great-
est. Therefore, with a high shear force, the microparticles have a greater driving force
to precipitate as small droplets. On the other hand, in the case of EVA/CORT-2, the
EVA+CORT stream was added slightly further away from the mixer paddle (closer to
the side of the beaker), where it is believed that the shear force is lower since the shear
force drops radially with relation to the mixer paddle. So with a lower shear force, there
is a lower driving force to precipitate the solution as smaller droplets, thus resulting in
microparticles that are slightly larger in size along with a more normal size distribution.
FIGURE 3.7: Left: SEM image of prepared EVA/CORT-2 microparticles.
Right: Size distribution histogram of EVA/CORT-2 microparticles.
3.4 Surface Characteristics
3.4.1 EVA Microparticles
In addition to using SEM to evaluate the morphology of the prepared EVA/CORT mi-
croparticles, SEM was used to gather images of the surfaces characteristics of the mi-
croparticles. Figure 3.8 displays the SEM images collected of the surface of the EVA
microparticles without CORT. As seen, the surface of the microparticles is not neces-
sarily smooth. Moreover, the surface has a clustered feature to it, that appears to be
composed of smaller clusters when seen at higher magnification.
3.4.2 EVA/CORT Microparticles
It is interesting to note that once the microparticles are prepared with CORT, the surface
characteristics change drastically. Figure 3.9 and 3.10 show SEM images collected of the
surface of EVA/CORT-1 and EVA/CORT-2 microparticles, respectively. Compared to
the EVA microparticles without CORT, the surfaces of these microparticles appear more
homogenous, i.e. they do not appear to have the clustered appearance that the EVA mi-
croparticles exhibited. This finding raises the thought that the EVA and CORT formed
a solid solution under the emulsification process, thereby producing this homogenous
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FIGURE 3.8: Left: surface of EVA microparticles without CORT. Right:
surface of EVA microparticles without CORT at higher magnification.
surface. However, the SEM images also show that the microparticles’ surfaces also ap-
pear to have pores and solid protrusions of material. These features are characteristic
of the solvent evaporation aspect of the preparation technique since once the solvent
evaporates, it either leaves behind a cavity in the material, or it causes the material to
warp and concomitantly leaves behind various features such as pores (O’Donnell and
McGinity, 1997; Chowdary and Babu, 2003). It has been determined in a past study that
these features, such as pore size, have a direct effect on the drug release capability of the
microparticle system (Chowdary and Babu, 2003).
FIGURE 3.9: Left: surface of EVA/CORT-1 microparticles. Right: surface
of EVA/CORT-1 microparticles at higher magnification.
3.5 In vitro Testing Results
To evaluate CORT release from the prepared EVA/CORT microparticles, thermogravi-
metric analysis (TGA) was used as an indirect measure. The theory behind using TGA
as the method for evaluating CORT release is due to weight loss percent of different
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FIGURE 3.10: Left: surface of EVA/CORT-2 microparticles. Right: sur-
face of EVA/CORT-2 microparticles at higher magnification.
components. Past studies in literature report that when TGA is run on EVA, the VA
burns off first, then followed by the PE backbone (Williams, 1994; Wenwei et al., 1994).
By analyzing the temperatures at which each component began and finished burning
off, the total weight percent that component made up of the sample could then be de-
termined.
Figure 3.11 below is a schematic (not data) that depicts the theory behind how such
TGA data was to be used in this study. Since the EVA used in this study is composed
of 12% VA, the TGA data from the EVA as-recieved should reflect a 12 wt% loss of
VA, then followed by the remaining wt% loss of the PE (Figure 3.10a). Then, once
the EVA/microparticles are prepared with CORT, the TGA data would reflect a new
weight loss before the VA weight loss, which would thus correspond to the CORT being
burnt off in the sample followed by the VA and PE loss (Figure 3.10b). Then, once the
EVA/CORT microparticles have been recovered after each day of in vitro testing, the
TGA data would reflect the same new weight loss, however in this case, the weight loss
would be smaller than the initial loading and previous days, therefore pointing towards
the action of CORT being released during the in vtiro experiment (Figure 3.10c). Using
this data then, after each day interval of testing, a CORT release profile curve would be
able to be constructed using the wt% loss (Figure 3.10d).
Despite the theory behind using TGA, the first interesting observation of the data
is a consistent false reading of the weight loss in one of the EVA/CORT microparticles
batches. In a majority of the samples from batch 2, after the samples were heated to
above about 300◦C, the weight loss reading dropped significantly to below 0 mg, then
rose to a value above the starting weight, and oscillated back and forth like this over
the course of about 75◦C, and then dropped back to normal with a final weight loss of
what appeared to be the PE in the sample (see appendix B for plots of this behavior).
This observation happened in about 3 of the days and samples tested. Table 3.2 below
gives a synopsis of the frequency of this false data occurrence. Because this behavior
is starkly different from the analytical approach described in Figure 3.10, those days
that exhibited this behavior could not be used to analyze any weight loss/release of
CORT. Due to unfortunate logistical events, TGA data after day 4 was not collected, and
therefore not included in this discussion.
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FIGURE 3.11: Theory of using TGA for evaluating CORT release indi-
rectly. Schematic TGA plots of A) EVA without CORT, B) EVA/CORT
microparticles at day 0 of in vitro testing, C) EVA/CORT microparticles
after day 5 of in vitro testing, and D) cumulative CORT release profile
curve generate using wt% loss after each day of in vitro testing.
TABLE 3.2: Frequency of aberration in TGA data for each batch and after
each day of in vitro testing.
Batch Day Aberration?
1 0 No
2 0 Yes
1 1 No
2 1 Yes
1 2 Yes
2 2 Yes
1 3 No
2 3 Yes
1 5 No
2 5 No
The TGA curves for the EVA as-received and EVA microparticles without CORT
are shown below in Figure 3.12. The two important, specific pieces of data in these
curves are 1. the temperature at which the VA begins to burn off, and 2. the weight
loss percent of the VA content. Figure 3.12a shows weight loss data of EVA as-received
that is consistent with literature (Williams, 1994) where the degradation temperature is
around 200 ◦C and the VA weight loss percent is 12%. Similarly, Figure 3.12b shows
a similar degradation temperature around 200 ◦C, but reflects a weight loss percent
of VA of 9.53%. The difference in weight loss percents points towards a speculation
already discussed: potential effects of processing the EVA into microparticles on the
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composition of EVA. Although, this is speculative since the difference in weight loss
percent is not greatly significant.
FIGURE 3.12: TGA curves of A) EVA as-received and B) EVA micropar-
ticles without CORT. Note the degradation temperatures and weight loss
percents.
TGA curves for those days in which aberrations were not experienced by EVA/CORT-
1 microparticles and EVA/CORT-2 microparticles are displayed in Figures 3.13 and
3.14, respectively. Initially, it is observed that the theorized first weight loss drop is not
present in any of these data. The curves still have the overall shape of EVA alone. How-
ever, an analysis of these curves show two interesting trends. First, it was observed that
as the days of in vitro testing progress, the degradation temperature increases as well,
from 200 ◦C to around 250 ◦C. Second, it was observed that the weight loss percent in-
creased, as the days of in vitro testing progressed. These trends are shown in Tables 3.3
and 3.4 for EVA/CORT-1 microparticles and EVA/CORT-2 microparticles, respectively.
TABLE 3.3: Summary of Degradation Temperatures and Weight Loss Per-
cents for EVA/CORT-1 Microparticles
Day Degradation Temperature (◦C) Weight Loss Percent
0 198.5 ◦C 12.82%
1 224.2 ◦C 16.12%
3 242.2 ◦C 16.71%
5 247 ◦C 18.99%
TABLE 3.4: Summary of Degradation Temperatures and Weight Loss Per-
cents for EVA/CORT-2 Microparticles
Day Degradation Temperature (◦C) Weight Loss Percent
0 235.8 ◦C 14.71%
5 251.8 ◦C 16.72%
Despite the absence of the first weight loss drop that would correspond to CORT,
these findings bring attention to various experimental parameters that would effect
CORT release. Since the degradation temperature of the EVA/CORT microparticles was
found to be higher than that of the EVA as-received and EVA microparticles without
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FIGURE 3.13: TGA curves of EVA/CORT-1 microparticles at A) day 0, B)
day 1, C) day 3, and D) day 5 of in vitro testing. Note the degradation
temperatures and weight loss percents.
FIGURE 3.14: TGA curves of EVA/CORT-2 microparticles at A) day 0
and B) day 5 of in vitro testing. Note the degradation temperatures and
weight loss percents.
CORT, it is interesting to speculate if the loading of CORT stabilized the microparticles
to a greater extent. This stabilization could then have caused the VA content to burn off
later, or it could have caused some solution of VA+CORT to burn off later if there was
indeed interactions between the CORT and EVA.
In addition to the possibility of the EVA/CORT microparticles becoming stabilized
when loaded with CORT, the increase in weight loss percent suggests an adverse effect
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during the in vitro tests. Since the EVA contained 12 % VA content, it is counterintuitive
that the weight loss percents are greater, and if the CORT release was part of the VA
content drop, it would be understandable that the weight loss percent would decrease,
however that was not the case. Considering these two details, the data suggests that
there was some event during the in vitro tests that caused the microparticles to cumu-
latively gain weight over the course of the five days. It is a possibility that during the
tests, a proportion of the Ringer’s solution infiltrated the microparticles via the pores
and/or cavities observed along the surfaces shown in Figures 3.9 and 3.10. This infiltra-
tion could then cause some of the salts to become entrapped in the microparticles which
therefore would contribute to a greater weight loss in addition to the VA content. By
this, the later days of the in vitro tests would yield higher weight loss percents than the
earlier days, which was the case for both EVA/CORT-1 and EVA/CORT-2. Considering
this finding, in addition to the increase in degradation temperatures, a CORT release
profile curve could not be constructed.
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Chapter 4
Conclusions
4.1 Preparation of EVA/CORT Microparticles
There exists a mismatch between the FTIR data of the EVA/CORT microparticles and
the TGA curves after in vitro testing. The FTIR spectra suggests the possibility of CORT
being encapsulated within the microparticles composed of EVA. However, the lack of a
distinct weight loss drop in the TGA data suggests that the only components within the
microparticles are VA and PE, the two components of EVA. Therefore, because of this
mismatch, it can be concluded that microparticles were prepared in this study. How-
ever, the presence of CORT within these microparticles could not be identified.
4.2 Evaluation of CORT Release
The evaluation of CORT release depended only on the TGA tests done on the micropar-
ticles after each day interval of in vitro testing. Since there were was not a distinct weight
loss drop in the EVA/CORT microparticles, the release of CORT could not be directly
determined from the TGA curves. Even more so, the finding of increased degradation
temperature and increased weight loss percent suggests that the effects of processing on
the microparticles and the effects of the in vitro experimental design prevented the inter-
pretation of CORT release. Therefore, because of this unfortunate findings, the release
of CORT from the microparticles could not be determined.
4.3 EVA/CORT Microparticle System
Considering the goal of this study, the conclusions regarding the preparation of the
microparticles and the evaluation of CORT release do not support the successful prepa-
ration of an implantable microparticle system that could release CORT at a controlled
rate. Until improvements are made, the EVA/CORT microparticle system would not
operate as desired in order to control CORT release and elevation in rattlesnakes.
4.4 Recommendations
The conclusions listed above do shine light, however, on new improvements to the con-
tinuation of this study. Future research into the EVA/CORT microparticle system of this
study would include two different components. First, the emulsification-solvent evap-
oration technique must include greater control of mixing conditions. A more precise
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technique of adding the EVA+CORT stream to the emulsifier would produce more dis-
crete microparticles that are of adequate size for use in rattlesnakes. Even more so, better
control of dissolving the CORT into the polymer solution would thus increase the like-
lihood of the presence of CORT in the microparticles in the first place. This would then
yield more intuitive results in characterization techniques to determine CORT presence.
The other component of recommendations for future research would include more
direct characterization techniques. In order to determine possible interactions between
the EVA and CORT, differential scanning calorimetry should be utilized in junction
with FTIR. More importantly, direct methods of evaluating CORT release should be
utilized. These methods would include techniques such as UV-vis spectroscopy, high-
performance liquid chromatography, or perhaps enzyme-linked immunosorbent assay
(ELISA) kits. These techniques could definitively determine whether or not CORT is
being released, and if so, the efficacy of controlled release. These improvements would
thereby enhance the viability of this microparticle design and moreover pave new ex-
citing avenues for implants that can enable conservation biologists new tools for deter-
mining the effect of the stress response on animals.
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Appendix A
Mixing Conditions
FIGURE A.1: Location of EVA+CORT stream added for EVA/CORT-1.
FIGURE A.2: Location of EVA+CORT stream added for EVA/CORT-2.
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Appendix B
Aberration Plots
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Appendix C
Bar Graphs
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FIGURE C.1: Bar graph of degredation temperatures for different condi-
tions of EVA/CORT-1 microparticles
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FIGURE C.2: Bar graph of weight loss percents for different conditions of
EVA/CORT-1 microparticles
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